Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > News out 👀

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Oct 26, 2022 9:51am

151 Views

Post# 35049366

RE:RE:RE:RE:News out 👀

We should also take note of the comment about other PDC's they are working on. We don't have any info on that other than they are working on some but there is potential for something else besides TH-1902 that perhaps builds on what they have learned so far. Having advanced some of this work already will only help the take-out share price if TH-1902 works and a potential acquirer wants to take THTX over.

qwerty22 wrote:
So if we assume that the patients they are enrolling match the population they have on these microarrays then we can expect of the 50 enrolled patients in the 5 main cancer arms that about 40 +/- might be Sort+ (H score >100). With 1-3 enrolled patients in each cancer type of the 5 main cancers being negative. That seems to me to be a reasonable scenario for continuing forward atm without Sortilin testing of enrolled patient. Just to be clear it's not that I don't think SORT testing should happen just that it doesn't need to be a priority just yet.

I guess one titbit we learn is, based on the authors, that Discovery Life Sciences are their partner for the assay development. From a technical perspective I guess the question I have is if the assay they've developed for this R&D is ready to be taken into the clinic and used on their enrolled patients.

https://www.dls.com/biomarker-services/tissue-biomarker-services

LouisW wrote:
I like the way CMO talked about the data. Sounds exciting and promising.